Abstract
The Journal does not ordinarily publish preliminary or incomplete reports of clinical trials. We have little interest in the early, inconclusive results of an ongoing study or the partial conclusions of a completed study to be published in a series of fragmented and overlapping reports. We prefer to reserve our pages for trials that have proceeded far enough to justify definite conclusions and reports that include all, not just some, of the results of a completed study.Why, then, do we publish as a Special Report in this week's issue1 the preliminary "Phase I" findings of a trial of intravenous . . .